Your browser doesn't support javascript.
loading
Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Dou, Jingtao; Ma, Jianhua; Liu, Jun; Wang, Changjiang; Johnsson, Eva; Yao, Hui; Zhao, June; Pan, Changyu.
Afiliación
  • Dou J; Department of Endocrinology, The General Hospital of People's Liberation Army, Beijing, China.
  • Ma J; Department of Endocrinology, Nanjing First Hospital, Nanjing, China.
  • Liu J; Department of Endocrinology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
  • Wang C; Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Johnsson E; Global Medicines Development, AstraZeneca, Gothenburg, Mölndal, Sweden.
  • Yao H; China Development Unit, AstraZeneca, Shanghai, China.
  • Zhao J; AstraZeneca, Gaithersburg, Maryland.
  • Pan C; Department of Endocrinology, The General Hospital of People's Liberation Army, Beijing, China.
Diabetes Obes Metab ; 20(3): 590-598, 2018 03.
Article en En | MEDLINE | ID: mdl-28926170

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adamantano / Diabetes Mellitus Tipo 2 / Dipéptidos / Hipoglucemiantes / Metformina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adamantano / Diabetes Mellitus Tipo 2 / Dipéptidos / Hipoglucemiantes / Metformina Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido